Analysts Set Stryker Co. (NYSE:SYK) Price Target at $290.89

Stryker Co. (NYSE:SYKGet Rating) has received an average recommendation of “Hold” from the twenty-three brokerages that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $290.89.

Several equities research analysts have commented on the stock. BTIG Research upped their target price on shares of Stryker from $273.00 to $278.00 in a research note on Monday, April 18th. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Monday, May 2nd. TheStreet downgraded shares of Stryker from a “b” rating to a “c+” rating in a research note on Monday, May 2nd. Truist Financial lowered their target price on shares of Stryker from $296.00 to $280.00 in a research note on Monday, May 2nd. Finally, Evercore ISI reaffirmed an “outperform” rating and issued a $284.00 target price on shares of Stryker in a research note on Tuesday, March 15th.

Several hedge funds and other institutional investors have recently bought and sold shares of SYK. Pinnacle Private Wealth LLC acquired a new stake in Stryker in the 4th quarter worth about $317,000. Captrust Financial Advisors raised its stake in Stryker by 16.5% in the 3rd quarter. Captrust Financial Advisors now owns 18,298 shares of the medical technology company’s stock worth $4,837,000 after purchasing an additional 2,585 shares in the last quarter. Beese Fulmer Investment Management Inc. raised its stake in Stryker by 1.3% in the 4th quarter. Beese Fulmer Investment Management Inc. now owns 37,924 shares of the medical technology company’s stock worth $10,142,000 after purchasing an additional 492 shares in the last quarter. American International Group Inc. raised its stake in Stryker by 0.7% in the 3rd quarter. American International Group Inc. now owns 117,477 shares of the medical technology company’s stock worth $30,981,000 after purchasing an additional 791 shares in the last quarter. Finally, ProShare Advisors LLC raised its stake in Stryker by 29.2% in the 4th quarter. ProShare Advisors LLC now owns 72,996 shares of the medical technology company’s stock worth $19,521,000 after purchasing an additional 16,484 shares in the last quarter. Institutional investors own 74.52% of the company’s stock.

Shares of NYSE SYK opened at $233.05 on Tuesday. The company’s 50 day simple moving average is $253.99 and its 200 day simple moving average is $256.56. Stryker has a fifty-two week low of $224.02 and a fifty-two week high of $281.16. The firm has a market capitalization of $88.13 billion, a P/E ratio of 44.31, a P/E/G ratio of 2.61 and a beta of 0.99. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.98 and a quick ratio of 1.18.

Stryker (NYSE:SYKGet Rating) last announced its quarterly earnings data on Thursday, April 28th. The medical technology company reported $1.97 earnings per share for the quarter, beating the consensus estimate of $1.93 by $0.04. Stryker had a net margin of 11.56% and a return on equity of 24.09%. The business had revenue of $4.30 billion for the quarter, compared to analyst estimates of $4.19 billion. During the same period in the prior year, the business posted $1.93 earnings per share. Stryker’s revenue was up 8.8% compared to the same quarter last year. Sell-side analysts expect that Stryker will post 9.64 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, July 29th. Stockholders of record on Thursday, June 30th will be paid a dividend of $0.695 per share. This represents a $2.78 dividend on an annualized basis and a dividend yield of 1.19%. The ex-dividend date of this dividend is Wednesday, June 29th. Stryker’s dividend payout ratio is presently 52.85%.

Stryker Company Profile (Get Rating)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.

Recommended Stories

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.